Reduction of angiogenesis in chorioallantoic membrane xenografted hepatocellular carcinomas by treatment with a decorin-expressing herpes simplex virus vector.

Fanny Frejborg, Oliver Koivisto, Roope Huttunen, Jessica M Rosenholm, Hongbo Zhang, Hannu Järveläinen, Veijo Hukkanen

Abstract read

In one paragraph

Article in Virology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Fanny FrejborgPharmaceutical Sciences Laboratory, Faculty of Science and Engineering, Åbo Akademi University, Turku, Finland. fanny.frejborg@abo.fi.

Oliver KoivistoPharmaceutical Sciences Laboratory, Faculty of Science and Engineering, Åbo Akademi University, Turku, Finland.

Roope HuttunenInstitute of Biomedicine, University of Turku, Turku, Finland.

Jessica M RosenholmPharmaceutical Sciences Laboratory, Faculty of Science and Engineering, Åbo Akademi University, Turku, Finland.

Hongbo ZhangPharmaceutical Sciences Laboratory, Faculty of Science and Engineering, Åbo Akademi University, Turku, Finland.

Hannu Järveläinen *Institute of Biomedicine, University of Turku, Turku, Finland. hanjar@utu.fi.

Veijo Hukkanen *Institute of Biomedicine, University of Turku, Turku, Finland. veijo.hukkanen@utu.fi.

Funding

Jane ja Aatos Erkon Säätiö 170046

6 · The paper itself

Abstract

Decorin is a proteoglycan that suppresses tumor growth and angiogenesis. We studied whether our recently constructed decorin-expressing herpes simplex virus (HSV) vector can reduce angiogenesis in xenografted liver carcinoma cells in the chorioallantoic membrane model. The vascularized tumors were treated with an overlay dose of our vector. The results show that the treatment reduced angiogenesis in the tumors by 60% (p = 0.005) four days after treatment, suggesting that decorin-expressing HSV vectors are a promising strategy for novel cancer therapies.

Indexed as

Carcinoma, HepatocellularChorioallantoic MembraneDecorinGenetic TherapyGenetic VectorsLiver NeoplasmsNeovascularization, PathologicSimplexvirusAnimalsCell Line, TumorHumansMiceDecorinAntiangiogenic agentDecorinGene therapyHerpes simplex vector

Identifiers

PMID42015278

DOI10.1186/s12985-026-03162-w

PMCPMC13262074

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.